A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of
TAK-536 (azilsartan) in pediatric patients aged 6 to less than 16 years with hypertension.